Overview

Rifaximin Prophylaxis for Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome in Cirrhotic Patients

Status:
Completed
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
Norfloxacin is the most commonly used drug for the prophylaxis against spontaneous bacterial peritonitis (SBP) in patients with liver cirrhosis. Rifaximin, another broad spectrum antibiotic with only trivial absorption from the gut, is used for the treatment of traveler's diarrhea and prevention of hepatic encephalopathy.
Phase:
Phase 2
Details
Lead Sponsor:
Samar Atef Sebaweh Mohammed
Treatments:
Rifaximin